{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49","value":"15020"},{"groupId":"OG001","spread":"17","value":"28600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 1/Day 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"16660"},{"groupId":"OG001","spread":"119","value":"31400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 1/Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received oral doses of glasdegib (PF-04449913) tablets 100 milligram (mg) starting on Day 3 of Cycle 1 for pharmacokinetic (PK) assessment purposes and thereafter once daily (QD) and continuously for 28-day cycles (starting on Day 1 for all other cycles). LDAC was given at a dose of 20 mg subcutaneously twice daily (BID) on Days 1-10 of the 28-day cycles.","id":"OG000","title":"Phase 1B: Glasdegib 100 mg + LDAC"},{"description":"Participants received oral doses of glasdegib tablets 200 mg starting on Day 3 of Cycle 1 for PK assessment purposes and thereafter QD and continuously for 28-day cycles (starting on Day 1 for all other cycles). LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28-day cycles. In March 2013, all active participants receiving glasdegib 200 mg were required to reduce dose to 100 mg. Participants who had glasdegib dose reduction were reported as the starting glasdegib dose level received. Two (2) participants in this cohort had dose reduction to 100 mg starting from Cycle 2/Day 1 and Cycle 2/Day 16, respectively.","id":"OG001","title":"Phase 1B: Glasdegib 200 mg + LDAC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Dose compliant group:Participants who had at least 4 days of uninterrupted dosing for a multiple dose PK assessment were considered to be at steady state,part of the \"dose compliant\" group.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours post-dose on Cycle 1/Day 10 and Cycle 1/Day 21","title":"Area Under the Plasma Concentration-time Profile From Time 0 to Dosing Interval (AUCtau) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}